Ozmpic-Maker CEO was overthrown on Rocky Market at Pharma Company

In a surprising and surprising development, CEO of OzemPic maker Novo Nordisk was expelled from his position as head of the company. On Friday, the Danish pharmaceutical giant announced that, amid a recent shrinkage in the shares of the company, Lars Fergard Juergen will soon step as the best executive, and the board of directors will search for a successor to it.

The company said in a press release: “According to the mutual agreement with the Novo Nordisk Council, Lars Frogaard J Prietsen will step down from his role as CEO of Novo Nordisk,” the company said in a press statement. “He will continue as an executive for a while to support the smooth transition to a new leadership.”

It is definitely strange that Novo Nordisk does not work well. After all, it’s the company behind a penetration drug, Smaglutide, can apparently make anyone – from Jim Javigan to OperaThe pound’s pound immediately. However, while OzemPIC and Wegovy have obtained a position as international home names, the price of Novo Nordisk has seen the price Big shrinkage During the past year, like Competitive brands I infiltrated the market. In its statement about the overthrow of Georgensen, the pharmaceutical company notes that the rapidly changing scene of weight loss products is what shook in the company’s leadership. “The changes are made in light of the recent challenges facing Noordisk Noordisk, and the development of the company’s share price since mid -2014.” press release From the company reads.

However, it is also noted that Georgessen managed the company’s sponsors to a better economic water for the best part of a decade before market problems arrived in 2024: “During his eight -year -old term as CEO, Novo Nordisk sales, profits and stock price have doubled almost three times,” the company wrote. “Given the recent market challenges, the decrease in the stock prices, and the desire of the Novo Nordisk Foundation, the Novo Nordisk Council and Lars Fergard Juergen jointly concluded that the start of the CEO of the CEO is in the interest of the company and the shareholders.”

Gizmodo has arrived at Novo Nordisk for more information and will update this story if you respond.